Synthego was founded in 2012 by Alex Pesch, Michael Dabrowski, and Paul Dabrowski. When asked about a potential IPO, CEO Dabrowski said that while "We think we can basically be ready for that anytime... From a publicity standpoint, from a people and teams standpoint, a financial capital needs standpoint, now we’ve decided to stay private." These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Synthego is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms at scale. The company is a major developer of the tools which are used in CRISPR therapies, citing more than 1,000 peer-reviewed studies that have used its technology in at least one step. The company has raised more than $450 million in venture capital funding from investors including Perceptive Advisors LLC, SoftBank Vision Fund 2, Moore Strategic Ventures, Declaration Partners, Laurion Capital Management, and Logos Capital. Synthego did not release valuation information after a $200 million equity round in early 2022, but it is estimated at between $800 million and $1.2 billion.
Synthego does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Synthego will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 2/17/2022 | Series E | $1.3B | $XXX.XX | $XXX.XX |
| 8/26/2020 | Series D | $486.63MM | $XXX.XX | $XXX.XX |
| 10/23/2018 | Series C | $381.27MM | $XXX.XX | $XXX.XX |
| 1/4/2017 | Series B and B-1 | $111MM | $XXX.XX | $XXX.XX |
| 7/5/2013 | Series A | $23.7MM | $XXX.XX | $XXX.XX |
